| scholarly article | Q13442814 |
| P50 | author | Steven G Deeks | Q57425986 |
| P2093 | author name string | Peter W Hunt | |
| Priscilla Y Hsue | |||
| P2860 | cites work | Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy | Q22251085 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Inflammatory and coagulation biomarkers and mortality in patients with HIV infection | Q28473903 | ||
| The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial | Q28475076 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
| Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? | Q33184007 | ||
| Interleukin-2 therapy in patients with HIV infection | Q33847543 | ||
| Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection | Q33857515 | ||
| Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection | Q33907642 | ||
| Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy | Q33962223 | ||
| Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals | Q33991362 | ||
| Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study | Q34011661 | ||
| HIV Infection, Inflammation, Immunosenescence, and Aging | Q34150710 | ||
| Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort | Q34204026 | ||
| Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads | Q34312257 | ||
| Inflammatory markers and the risk of coronary heart disease in men and women | Q34376967 | ||
| Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy | Q34384143 | ||
| Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System | Q34564981 | ||
| A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response | Q34743336 | ||
| Changes in the risk of death after HIV seroconversion compared with mortality in the general population | Q34791057 | ||
| Cardiovascular implications from untreated human immunodeficiency virus infection | Q34793193 | ||
| Cardiovascular risk and body-fat abnormalities in HIV-infected adults | Q36000980 | ||
| Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy | Q36304297 | ||
| CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection | Q36745251 | ||
| State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary | Q36812073 | ||
| Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. | Q37016796 | ||
| Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. | Q37057982 | ||
| The role of HIV in serious diseases other than AIDS. | Q37186467 | ||
| Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy | Q37200979 | ||
| Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis | Q37215251 | ||
| HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity | Q37378238 | ||
| Association of C-reactive protein and HIV infection with acute myocardial infarction | Q37390630 | ||
| Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease | Q37390635 | ||
| Untreated HIV infection and large and small artery elasticity | Q37393762 | ||
| Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy | Q37496608 | ||
| Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. | Q37570619 | ||
| Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial | Q38473723 | ||
| Coronary aging in HIV-infected patients | Q39035151 | ||
| C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany | Q40524614 | ||
| Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study | Q42992133 | ||
| C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s | Q43833652 | ||
| Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 | ||
| Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection | Q44801351 | ||
| Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Q57181081 | ||
| Coronary heart disease in HIV-infected individuals | Q73687564 | ||
| Rheumatoid arthritis and heart disease | Q82759381 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | S375-82 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Immunologic basis of cardiovascular disease in HIV-infected adults | |
| P478 | volume | 205 Suppl 3 |
| Q35510401 | 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque |
| Q93358660 | Abnormal Cerebral Perfusion Profile in Older Adults with HIV-Associated Neurocognitive Disorder: Discriminative Power of Arterial Spin-Labeling |
| Q36919221 | Accelerated Aging in HIV Patients |
| Q64119443 | Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women |
| Q38958817 | Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals |
| Q39077480 | Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems |
| Q42376865 | Association between eczema and major cardiovascular outcomes in population-based studies: a systematic review protocol |
| Q94468720 | Association between statin use, atherosclerosis, and mortality in HIV-infected adults |
| Q37643812 | Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection |
| Q39086018 | Association of Kidney Function and Early Kidney Injury With Incident Hypertension in HIV-Infected Women |
| Q52725458 | Atrial arrhythmia prevalence and characteristics for human immunodeficiency virus-infected persons and matched uninfected controls. |
| Q34841938 | CD4 T Cells Mediate Both Positive and Negative Regulation of the Immune Response to HIV Infection: Complex Role of T Follicular Helper Cells and Regulatory T Cells in Pathogenesis |
| Q28910367 | CD4 ligation on human blood monocytes triggers macrophage differentiation and enhances HIV infection |
| Q57679623 | Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G |
| Q89521316 | Cardiovascular Biomarker Profile on Antiretroviral Therapy Is Not Influenced by History of an IRIS Event in People With HIV and Suppressed Viremia |
| Q39405054 | Cardiovascular Disease Risk Prediction in the HIV Outpatient Study |
| Q30245373 | Cardiovascular Disease, Statins, and HIV |
| Q35203971 | Cardiovascular disease in HIV patients: from bench to bedside and backwards. |
| Q38206287 | Cardiovascular disease in human immunodeficiency virus |
| Q40074176 | Cardiovascular disease risk among women living with HIV in North America and Europe |
| Q44504250 | Cardiovascular disease risk assessment in HIV: navigating data-sparse zones. |
| Q35064091 | Cardiovascular disease risk in an aging HIV population: not just a question of biology. |
| Q44902091 | Cardiovascular profile and events of US adults 20-49 years with HIV: results from the NHANES 1999-2008. |
| Q97425625 | Cardiovascular, endothelial function, and immune markers in response to treatment with a polysaccharide in HIV+ adults in a randomized, double-blind placebo-controlled trial |
| Q64083802 | Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults |
| Q30366554 | Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals |
| Q50138604 | Changes in inflammation but not in T cell activation precede non-AIDS-defining events in a case-control study of patients on long-term antiretroviral therapy |
| Q33850487 | Comparison of the Peripheral Reactive Hyperemia Index with Myocardial Perfusion Reserve by 82Rb PET/CT in HIV-Infected Patients |
| Q33599291 | Contribution of intestinal barrier damage, microbial translocation and HIV-1 infection status to an inflammaging signature |
| Q36668917 | Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis |
| Q33900251 | Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. |
| Q38852476 | D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda |
| Q39293076 | Differences by HIV serostatus in coronary artery disease severity and likelihood of percutaneous coronary intervention following stress testing |
| Q37122279 | Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy |
| Q40606279 | Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection |
| Q30360288 | Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients. |
| Q36562863 | Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men |
| Q34553819 | Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort |
| Q41996168 | Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. |
| Q35338096 | Epidemiology and management of antiretroviral-associated cardiovascular disease |
| Q93053174 | Extracellular vesicles and chronic inflammation during HIV infection |
| Q92349506 | Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus |
| Q37626254 | Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals |
| Q40306994 | Greater Risk of Stroke of Undetermined Etiology in a Contemporary HIV-Infected Cohort Compared with Uninfected Individuals. |
| Q35579905 | HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque |
| Q36071230 | HIV Infection Is Not Associated with Carotid Intima-Media Thickness in Brazil: A Cross-Sectional Analysis from the INI/ELSA-Brasil Study |
| Q50045865 | HIV and Cardiovascular Disease: Role of Immunometabolic Perturbations |
| Q38005046 | HIV and inflammation: mechanisms and consequences |
| Q34494208 | HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4. |
| Q40546493 | HIV, Cocaine Use, and Hepatitis C Virus: A Triad of Nontraditional Risk Factors for Subclinical Cardiovascular Disease |
| Q38649363 | HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review |
| Q34653277 | HIV-associated chronic immune activation |
| Q36327164 | HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation |
| Q34482615 | HIV-infection, atherosclerosis and the inflammatory pathway: candidate gene study in a Spanish HIV-infected population |
| Q41932859 | Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls. |
| Q26801331 | Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries |
| Q26824782 | Human immunodeficiency virus-associated pulmonary arterial hypertension |
| Q35005668 | IL-1Β enriched monocytes mount massive IL-6 responses to common inflammatory triggers among chronically HIV-1 infected adults on stable anti-retroviral therapy at risk for cardiovascular disease |
| Q36556082 | Immune activation and cardiovascular disease in chronic HIV infection |
| Q60957273 | Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals |
| Q30278586 | Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda |
| Q40196920 | Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population |
| Q36862952 | Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers |
| Q37086410 | Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men |
| Q37195784 | Infectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus Infection |
| Q60046139 | Influence of Physical Exercise on Advanced Glycation End Products Levels in Patients Living With the Human Immunodeficiency Virus |
| Q33649200 | Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? |
| Q36238363 | Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients |
| Q35220407 | Investigating the role of ankyrin-rich membrane spanning protein in human immunodeficiency virus type-1 Tat-induced microglia activation |
| Q38991136 | Low prevalence of peripheral arterial disease in a cross-sectional study of Danish HIV-infected patients |
| Q39404652 | Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection |
| Q64122946 | Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study |
| Q33828507 | Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers |
| Q59798114 | Metabolically Healthy or Metabolically Unhealthy Obese HIV-Infected Patients: Mostly a Matter of Age? |
| Q34292033 | Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS production |
| Q39622641 | Non-linear resistance training reduces inflammatory biomarkers in persons living with HIV: A randomized controlled trial |
| Q37176330 | Normal Myocardial Flow Reserve in HIV-Infected Patients on Stable Antiretroviral Therapy: A Cross-Sectional Study Using Rubidium-82 PET/CT. |
| Q35049714 | Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations |
| Q36440262 | Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy |
| Q36996000 | Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women |
| Q57160588 | Plasma glycomics predict cardiovascular disease in patients with ART-controlled HIV infections |
| Q30151768 | Preparedness of HIV care and treatment clinics for the management of concomitant non-communicable diseases: a cross-sectional survey |
| Q38730051 | Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis |
| Q37410810 | Prevalence of Hypertension and Its Associated Risk Factors among 34,111 HAART Naïve HIV-Infected Adults in Dar es Salaam, Tanzania |
| Q35994802 | Preventing Heart Failure in Inflammatory and Immune Disorders |
| Q26774828 | Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic Review |
| Q37662724 | RYR3 gene variants in subclinical atherosclerosis among HIV-infected women in the Women's Interagency HIV Study (WIHS). |
| Q38748465 | Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults. |
| Q37572266 | Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy. |
| Q34516572 | Retinal arterioles narrow with increasing duration of anti-retroviral therapy in HIV infection: a novel estimator of vascular risk in HIV? |
| Q34774826 | Risk factors for subclinical atherosclerosis in HIV-infected patients under and over 40 years: a case-control study |
| Q37556442 | Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV. |
| Q38183454 | Role of inflammation in HIV-1 disease progression and prognosis |
| Q26753830 | START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection |
| Q33899641 | Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection |
| Q37320521 | Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. |
| Q64284086 | Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use |
| Q35089263 | Stimulating high impact HIV-related cardiovascular research: recommendations from a multidisciplinary NHLBI Working Group on HIV-related heart, lung, and blood disease |
| Q92885360 | Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection |
| Q47610317 | The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis |
| Q47161152 | The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review |
| Q28535156 | The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit |
| Q35097454 | Traditional risk factors are more relevant than HIV-specific ones for carotid intima-media thickness (cIMT) in a Brazilian cohort of HIV-infected patients |
| Q34430248 | Tumor necrosis factor α is associated with viral control and early disease progression in patients with HIV type 1 infection |
| Q56911208 | Undetectable = Untransmittable and Your Health: The personal benefits of early and continuous therapy for HIV infection |
| Q40136183 | Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis |
Search more.